

STable 1 Prevalence of medical comorbidities in patients with psoriasis vs. comparison of two groups in baseline and 12 months follow-up period.

Variable	Baseline			12 months follow-up period		
	Control	Psoriasis	p-value ²	Control	Psoriasis	p-value ²
	group,	group,		group,	group,	
	n	n		n	n	
	20,678 ¹	20,678 ¹		20,678 ¹	20,678 ¹	
Thyroid Cancer	11 (<0.1%)	23 (0.1%)	0.040	22 (0.1%)	29 (0.1%)	0.3
AIDS	19 (<0.1%)	12 (<0.1%)	0.2	27 (0.1%)	16 (<0.1%)	0.093
Autoimmune Thyroid Disease	14 (<0.1%)	24 (0.1%)	0.1	29 (0.1%)	41 (0.2%)	0.2
Lymphoma	14 (<0.1%)	12 (<0.1%)	0.7	24 (0.1%)	17 (<0.1%)	0.3
Obesity	16 (<0.1%)	23 (0.1%)	0.3	41 (0.2%)	33 (0.2%)	0.4
Metabolic Syndrome	5 (<0.1%)	2 (<0.1%)	0.5	2 (<0.1%)	0 (0%)	0.5
Thyroiditis	59 (0.3%)	82 (0.4%)	0.052	98 (0.5%)	104 (0.5%)	0.7
Thyroid Disease	740 (3.6%)	774 (3.7%)	0.4	902 (4.4%)	892 (4.3%)	0.8
Nonalcoholic Steatohepatitis (NASH)	0 (0%)	4 (<0.1%)	0.125	1 (<0.1%)	0 (0%)	>0.9

¹n (%)

²Fisher's exact test; The χ^2 test of independence.